Similarly, PAP might not be an issue when treating COVID-19 patients, because a single intravenous dose of monoclonal antibodies typically wears off in a month, at variance with the chronic deficiency of GM-CSF observed in PAP (Bonaventura et al., 2020). Here, CSF2 is linked to COVID-19.